Long-term efficacy of xamoterol (a beta 1-adrenoceptor partial agonist) in patients with mild to moderate heart failure.
This study was designed to assess the efficacy of xamoterol in 14 patients with mild to moderate heart failure over a period of 18 months. A beneficial effect on exercise capacity and a lowering of heart rate on exercise was sustained, and ejection fraction did not change, although some deterioration may be expected over this length of time in patients with heart failure. Xamoterol is safe and effective, and its benefits are maintained over at least 18 months.
Sørensen
E V
EV
Department of Internal Medicine and Cardiology, Arhus Amtssygehus, Denmark.
Faergeman
O
O
Day
M A
MA
Snow
H M
HM
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000368:Aged; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*; D017307:Xamoterol
D000318:Adrenergic beta-Agonists; D011412:Propanolamines; D017307:Xamoterol